ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 583

What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis?  Implications for Instrument Reduction

Proton Rahman1, Michel Zummer2, Wojciech Olszynski3, Majed Khraishi4, Dalton Sholter5, Rafat Faraawi6, William Bensen7, Milton Baker8, Andrew Chow9, Julie Vaillancourt10, John S. Sampalis10, Francois Nantel11, Allen J Lehman12, Susan Otawa12 and May Shawi11, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Université de Montréal, Montreal, QC, Canada, 3University of Saskatchewan, Saskatoon, SK, Canada, 4Nexus Clinical Research, St John's, NF, Canada, 5University of Alberta, Edmonton, AB, Canada, 6McMaster University, Hamilton, ON, Canada, 7Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 8University of Victoria, Victoria, BC, Canada, 9University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Janssen Inc., Toronto, ON, Canada, 12Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy and registry, Disease Activity, Health Assessment Questionnaire

  • Tweet
  • Email
  • Print
Session Information

Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease activity, they have been critiqued for being time-consuming, not convenient on a daily-basis and thus not contributing to decisions in routine care. The aim of this analysis was to describe the correlation of individual HAQ and BASDAI questions with patient and physician reported measures used in ankylosing spondylitis (AS) and to examine whether the instruments could be reduced to better reflect routine clinical practice.

Methods BioTRAC is an ongoing prospective registry of patients initiating infliximab or golimumab as first biologics or after <6 months of biologic treatment. Data from AS patients treated in 2005-2014 were used. The correlation of individual HAQ and BASDAI questions with patient (pain, BASDAI, HAQ and BASFI) and physician (MDGA) reported measures was described with the Pearson's correlation coefficient. The impact of each question on the need for help in each HAQ domain was assessed with logistic regression. Factor analysis was used to assess the variability due to each individual question in HAQ and BASDAI.

Results A total of 413 AS patients with 1660 BASDAI and 1654 HAQ assessments were included. HAQ and BASDAI questions correlated at different extents with each AS measure (Table 1). Questions related to “eating” and “gripping” showed the lowest correlation with patient and physician reported measures. All HAQ questions had higher correlations with patient reported measures than with MDGA. The BASDAI question on “fatigue and tiredness” showed the highest correlation with BASFI, while the question on “other joints pain/swelling” showed the lowest correlation with MDGA. None of the HAQ and BASDAI questions were associated with needing help for eating. All other HAQ individual questions were significantly associated with the need for help within their corresponding category, with the exception of Q5C and Q7A. BASDAI question on level of discomfort was significantly associated with the need for help in all HAQ categories, with the exception of “eating” and “walking”. Q2A and Q7C accounted for 59.6% of the HAQ variance. The level of morning stiffness accounted for 73.8% of the BASDAI variance. When combining the HAQ and BASDAI, Q2A and Q3A from HAQ and Q1 from BASDAI accounted for 63.5% of the variance.

Conclusion Variability exists in the correlation of HAQ and BASDAI questions with patient and physician reported AS measures. The results suggest that “standing up straight from an armless chair” and “turning faucets on/off” are the main drivers of HAQ, while the level of morning stiffness drives the BASDAI. Three questions were found to drive the combined HAQ and BASDAI which may have implications in the design of self-report instruments. 

Table 1. Correlation between Individual HAQ / BASDAI Questions and Disease Activity Measures

HAQ Questions

Pain

BASDAI

BASFI

MDGA

Dressing and Grooming (Q.1 A/B)

0.56/0.41

0.53/0.45

0.68/0.52

0.47/0.37

Arising (Q.2 A/B)

0.60/0.63

0.63/0.66

0.74/0.66

0.50/0.54

Eating (Q.3 A/B/C)

0.32/0.27/0.34

0.36/0.31/0.39

0.36/0.36/0.42

0.24/0.22/0.25

Walking (Q.4 A/B)

0.52/0.54

0.55/0.58

0.63/0.68

0.43/0.45

Hygiene (Q.5 A/B/C)

0.51/0.40/0.50

0.54/0.44/0.53

0.63/0.65/0.60

0.43/0.35/0.44

Reach (Q.6 A/B)

0.47/0.53

0.52/0.57

0.68/0.72

0.37/0.44

Grip (Q.7 A/B/C)

0.33/0.33/0.28

0.28/0.40/0.35

0.38/0.40/0.33

0.26/0.26/0.25

Activities (Q.8 A/B/C)

0.56/0.57/0.60

0.58/0.58/0.62

0.67/0.67/0.72

0.46/0.48/0.52

HAQ-DI score

0.67

0.71

0.87

0.55

BASDAI Questions

Pain

HAQ-DI

BASFI

MDGA

Fatigue and tiredness (Q. 1)

0.74

0.58

0.87

0.62

Neck, back or hip pain (Q. 2)

0.85

0.66

0.77

0.67

Other joints pain/swelling (Q. 3)

0.66

0.60

0.67

0.53

Level of discomfort (Q. 4)

0.72

0.63

0.71

0.60

Level of morning stiffness (Q. 5)

0.80

0.64

0.76

0.69

Morning stiffness duration (Q. 6)

0.63

0.60

0.65

0.60

BASDAI score

0.85

0.71

0.82

0.72

* Levels of correlation are Weak: r <0.30; Moderate: r =0.30 - 0.39; Strong: r =0.40 - 0.69; and

Very Strong: r ≥0.70


Disclosure:

P. Rahman,

Consulting fees for Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer and Roche,

5;

M. Zummer,

Janssen Inc.,

5;

W. Olszynski,

Janssen Inc.,

5;

M. Khraishi,

Janssen Inc.,

5;

D. Sholter,

Janssen Inc.,

5;

R. Faraawi,

Janssen Inc.,

5;

W. Bensen,

Janssen Inc.,

5;

M. Baker,

Janssen Inc.,

5;

A. Chow,

Janssen Inc.,

5;

J. Vaillancourt,
None;

J. S. Sampalis,
None;

F. Nantel,

Janssen Inc.,

3;

A. J. Lehman,

Janssen Inc.,

3;

S. Otawa,

Janssen Inc.,

3;

M. Shawi,

Janssen Inc.,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-correlation-of-individual-haq-and-basdai-questions-with-disease-activity-measures-in-ankylosing-spondylitis-implications-for-instrument-reduction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology